Insulin sensitization therapy and the heart

focus on metformin and thiazolidinediones

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.
    Original languageEnglish
    Pages (from-to)539-50
    Number of pages12
    JournalHeart Failure Clinics
    Volume8
    Issue number4
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Thiazolidinediones
    Metformin
    Heart Failure
    Insulin
    Therapeutics
    Capillary Permeability
    Sodium
    Incidence

    Cite this

    @article{020362eb685941b8b6070c2ece72d39b,
    title = "Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones",
    abstract = "Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.",
    author = "Wong, {Aaron K. F.} and Struthers, {Allan D.} and Choy, {Anna Maria J.} and Lang, {Chim C.}",
    note = "Copyright 2012 Elsevier B.V., All rights reserved.",
    year = "2012",
    doi = "10.1016/j.hfc.2012.06.002",
    language = "English",
    volume = "8",
    pages = "539--50",
    journal = "Heart Failure Clinics",
    issn = "1551-7136",
    publisher = "Elsevier",
    number = "4",

    }

    TY - JOUR

    T1 - Insulin sensitization therapy and the heart

    T2 - focus on metformin and thiazolidinediones

    AU - Wong, Aaron K. F.

    AU - Struthers, Allan D.

    AU - Choy, Anna Maria J.

    AU - Lang, Chim C.

    N1 - Copyright 2012 Elsevier B.V., All rights reserved.

    PY - 2012

    Y1 - 2012

    N2 - Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.

    AB - Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.

    UR - http://www.scopus.com/inward/record.url?scp=84864739125&partnerID=8YFLogxK

    U2 - 10.1016/j.hfc.2012.06.002

    DO - 10.1016/j.hfc.2012.06.002

    M3 - Article

    VL - 8

    SP - 539

    EP - 550

    JO - Heart Failure Clinics

    JF - Heart Failure Clinics

    SN - 1551-7136

    IS - 4

    ER -